Merrill Lynch analyst Michael Cherny maintained a Buy rating on CVS Health Corp (NYSE:CVS) on Tuesday, setting a price target of $83, which is more or less 9.11 % above the present share price of $76.07.
Cherny expects CVS Health Corp to post earnings per share (EPS) of $0.93 for the first quarter of 2021.
The analysts priced targets range from a high of $101 to a low of $61.
From the latest earnings report of its, released on 09/30/2020, the company found a quarterly revenue of $67.06 billion and a net benefit of $3.25 billion. The company’s market cap is $99.57 billion.
Based on TipRanks.com, Merrill Lynch analyst Michael Cherny is currently ranked with four stars on a 0 5 stars ranking scale, with an average return of 11.5 % as well as a 60.53 % success rate.
CVS Health Corp. engages in the provision of health care services. It works through the following segments: Pharmacy Services, retail or Long Term Care, Health Care Benefits, and Corporate. The Pharmacy Services segment provides pharmacy benefit management strategies. The retail or Long Term Care segment includes offering of prescription drugs and assortment of general merchandise.
The Health Care Benefits segment offers quite traditional, voluntary and consumer-directed health insurance products as well as similar services, including medical, pharmacy, dental, behavioural health, medical relief capabilities. The Corporate segment involves in providing administrative services as well as management. The company was created by Stanley P. Goldstein and Ralph Hoagland in 1963 and is headquartered in Woonsocket, RI.